MIDD can ease pediatric & rare disease drug loss in Japan
Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…
Certara2025 年 7 月 8 日
Accelerating Oncology Drug FDA Submission with Project Management Services
Discover how Certara’s dedicated project management and pharmacometric support helped an emerging biotech company fast-track…
Certara2025 年 7 月 2 日
How Model-informed drug development rescue projects from a risky situation
Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…
Certara2025 年 6 月 26 日
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…
Certara2025 年 6 月 8 日
Unlocking the Power of Oligonucleotide Therapeutics: A Model-Informed Approach with Certara & Ionis
Clinical Pharmacology Leader, Ionis Pharmaceuticals Pratap Singh, Ph.D., is currently an Executive Director and Franchise…
Certara2025 年 4 月 3 日
